The U.S. Food and Drug Administration (FDA) has approved the drug Radicava (edaravone) to treat ALS/MND in the USA. Shown to slow progression in some people, it is the first drug to be approved for ALS in over 20 years (it is anticipated Radicava will be available in the U.S. by August 2017). In 2015, edaravone was approved for use as an ALS treatment in Japan (as Radicut) and South Korea. Radicava is administered through an intravenous infusion and not yet approved for use in Australia under our country's regulatory approval process for drugs. In this report we provide information about edaravone and the Australian context.